Dear doctor Hickey. Reading your excellent article, I couldn’t help but think that there is no mention that if the people surveyed are taking psychiatric medications, therefore, the possible link of brain differences due to exposure to these medications, as is the case with neuroleptics and people who have been diagnosed with schizophrenia. Where, as I recall, it has been proven that the cause of the reduction in gray mass is due to the chronic exposure to so-called antipsychotics or the blocking of the dopamine pathways. Therefore, if a person has received the diagnosis of MDD, it is not assumed that the first line treatment is with SSRIs or other toxins such as lithium? which could affect the chronic patient (consumer) in a similar way. Isn’t that a possibility? Any ideas or comments about it?